NCT02866747 2026-04-14
STERIMGLI
Institut Claudius Regaud
Phase 1/2 Completed
Clinical Trials
130 trialsNCT04801147 2026-03-27
DENDR1
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 1/2 Completed
NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT03529448 2026-02-12
GEINOCANN
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT04440358 2026-01-20
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
Phase 1/2 Completed
NCT04116658 2025-11-28
ROSALIE
Enterome
Phase 1/2 Completed
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01478178 2025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
Phase 1/2 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT07120620 2025-08-13
PriCoTTF
University Hospital, Essen
Phase 1/2 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03782415 2025-05-21
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
MediciNova
Phase 1/2 Completed
NCT03665545 2025-05-13
IMA950-106
University Hospital, Geneva
Phase 1/2 Completed
NCT02715609 2025-04-10
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase 1/2 Completed
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT03914742 2025-01-14
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01291420 2024-12-09
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
Phase 1/2 Completed
NCT03234595 2024-09-19
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Everfront Biotech Co., Ltd.
Phase 1/2 Completed
NCT06562621 2024-08-20
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
Phase 1/2 Completed
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT02490800 2024-06-26
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
Phase 1/2 Completed
NCT03466450 2024-03-28
GEINOGLAS
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT01811498 2024-01-30
Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Northwell Health
Phase 1/2 Completed
NCT01128218 2023-11-30
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Southern Illinois University
Phase 1/2 Completed
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT04119674 2023-09-22
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
Zhejiang Cancer Hospital
Phase 1/2 Completed
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00662506 2023-06-06
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT03849105 2023-04-14
IPAX-1
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 1/2 Completed
NCT04657315 2023-01-18
MSC11FCD-GBM
CHA University
Phase 1/2 Completed
NCT04444427 2022-12-23
Evaluation of GLR2007 for Advanced Solid Tumors
Gan and Lee Pharmaceuticals, USA
Phase 1/2 Completed
NCT01177397 2022-12-13
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT01301430 2022-11-21
ParvOryx01
Oryx GmbH & Co. KG
Phase 1/2 Completed
NCT00687765 2022-09-14
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Sanofi
Phase 1/2 Completed
NCT03744026 2022-09-07
SC9-GBM-01
CarThera
Phase 1/2 Completed
NCT00731731 2022-08-04
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01062399 2022-06-09
RTOG 0913
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT01434602 2022-06-01
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02750891 2022-04-12
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT02770378 2021-10-05
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
Phase 1/2 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT01120639 2021-08-06
Tx-Treatment
Stanford University
Phase 1/2 Completed